$13.850
+0.906 (+6.54%)Zum Schluss
SNSE-News
SNSE-Events
Sensei Biotherapeutics Acquires Faeth Therapeutics and Raises $200 Million
"The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors," said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. "This acquisition and injection of new capital will allow us to advance PIKTOR, a differentiated multi-node pathway inhibitor, through key clinical milestones."
Sensei Biotherapeutics Begins HR+/HER2- Breast Cancer Trial
Sensei Biotherapeutics announced that the first patient was dosed in Study FTH-PIK-101, a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead program after the company acquired Faeth Therapeutics in February 2026.
Sensei Biotherapeutics Files to Sell 24.87M Shares of Common Stock
Sensei Biotherapeutics files to sell 24.87M shares of common stock for holders
Sensei Biotherapeutics 2026 Clinical Trial Progress
"2025 was a year of focus and discipline for Sensei, and with the addition of Faeth and injection of new capital, we are entering 2026 with a clear path forward," said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. "We are now focused on advancing PIKTOR through key clinical milestones, including topline data from the ongoing Phase 2 trial in advanced endometrial cancer and initiation of the planned Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year-end 2026."
Sensei Biotherapeutics Grants New Employee 166,435 Stock Options
Sensei Biotherapeutics announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435 shares of the Company's common stock in connection with their employment. The Option Award was granted as an inducement material to the individual entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Award has an exercise price of $29.37, which is equal to the closing price of Sensei's common stock on March 11, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the date of grant, with the remaining shares vesting in equal monthly installments over a three-year period, in each case subject to such employee's continued service with Sensei through each such vesting date.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.